Clinical Pharmacokinetics

, Volume 53, Issue 7, pp 611–624 | Cite as

Pharmacokinetics of Antiretrovirals in Genital Secretions and Anatomic Sites of HIV Transmission: Implications for HIV Prevention

Review Article

Abstract

The incidence of HIV remains alarmingly high in many parts of the world. Prophylactic use of antiretrovirals, capable of concentrating in the anatomical sites of transmission, may reduce the risk of infection after an unprotected sexual exposure. To date, orally and topically administered antiretrovirals have exhibited variable success in preventing HIV transmission in large-scale clinical trials. Antiretroviral mucosal pharmacokinetics may help explain the outcomes of these investigations. Penetration and accumulation of antiretrovirals into sites of transmission can influence dosing strategies and pre-exposure prophylaxis clinical trial design. Antiretroviral tissue distribution varies widely within and between drug classes, attributed in part to their physicochemical properties and tissue-specific drug transporter expression. Nucleoside(-tide) reverse transcriptase inhibitors, the CCR5 antagonist maraviroc, and the integrase inhibitor raltegravir demonstrate the highest penetration into the male and female reproductive tracts and colorectal tissue relative to blood. This review describes antiretroviral exposure in anatomic sites of transmission, and places these findings in context with the prevention of HIV and the efficacy of pre-exposure prophylactic strategies.

References

  1. 1.
    Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22–9.PubMedGoogle Scholar
  2. 2.
    Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, Sabin C, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;24(1):123–37.PubMedGoogle Scholar
  3. 3.
    Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–60.PubMedGoogle Scholar
  4. 4.
  5. 5.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMedGoogle Scholar
  7. 7.
    Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34(9):875–92.PubMedGoogle Scholar
  11. 11.
    Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29(5):484–94.PubMedGoogle Scholar
  12. 12.
    Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362(24):2282–94.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999;43(8):1817–26.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Thompson CG, Cohen MS, Kashuba AD. Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S240–7.PubMedGoogle Scholar
  15. 15.
    Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149–67.PubMedGoogle Scholar
  16. 16.
    Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet. 1998;34(3):203–18.PubMedGoogle Scholar
  17. 17.
    Vishwanathan SA, Guenthner PC, Lin CY, Dobard C, Sharma S, Adams DR, et al. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr. 2011;57(4):261–4.PubMedGoogle Scholar
  18. 18.
    Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr. 2009;51(5):546–53.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Adams JL, Patterson KB, Prince HM, Sykes C, Greener BN, Dumond JB, et al. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. Antivir Ther. 2014;18(8):1005–13.Google Scholar
  21. 21.
    Thompson CG, Rosen E, Sykes C, Fedoriw Y, Luciw P, Muddiman DC, et al. Characterizing antiretroviral distribution within active viral reservoirs using mass spectrometry imaging. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; 19–21 May 2014; Washington, DC.Google Scholar
  22. 22.
    Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 2010;85(1):39–58.PubMedGoogle Scholar
  23. 23.
    Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007;21(14):1899–907.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Kwara A, Delong A, Rezk N, Hogan J, Burtwell H, Chapman S, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis. 2008;46(5):719–25.PubMedGoogle Scholar
  25. 25.
    Nicol MR, Kashuba AD. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther. 2010;88(5):598–609.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retrovir. 2013;29(11):1443–50.PubMedGoogle Scholar
  27. 27.
    Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci. 2010;31(1):22–35.PubMedGoogle Scholar
  28. 28.
    Gunawardana M, Mullen M, Moss JA, Pyles RB, Nusbaum RJ, Patel J, et al. Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One. 2013;8(10):e77340.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Zhou T, Hu M, Cost M, Poloyac S, Rohan L. Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research. AIDS Res Hum Retrovir. 2013;29(11):1496–503.PubMedGoogle Scholar
  30. 30.
    Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, Poindexter A, et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One. 2011;6(10):e25974.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 2013;8(1):e55013.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338(18):1281–92.PubMedGoogle Scholar
  33. 33.
    Patterson K, Jennings S, Falcon R, Mrus J, Kashuba A. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother. 2011;55(3):1120–2.PubMedCentralPubMedGoogle Scholar
  34. 34.
    Launay O, Tod M, Louchahi K, Belarbi L, Bouchaud O, Memain N, et al. Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob Agents Chemother. 2004;48(2):632–4.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retrovir. 2003;19(9):825–35.PubMedGoogle Scholar
  36. 36.
    Salas Herrera IG, Pearson RM, Turner P. Quantitation of albumin and alpha-1-acid glycoprotein in human cervical mucus. Hum Exp Toxicol. 1991;10(2):137–9.PubMedGoogle Scholar
  37. 37.
    Avery LB, Zarr MA, Bakshi RP, Siliciano RF, Hendrix CW. Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect. AIDS Res Hum Retrovir. 2013;29(11):1434–42.PubMedGoogle Scholar
  38. 38.
    Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, et al. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: implications for drug disposition in HIV prevention. J Clin Pharmacol. 2014;54(5):574–83.Google Scholar
  39. 39.
    Clavel C, Peytavin G, Tubiana R, Soulie C, Courbon E, Crenn-Hebert C, et al. Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study. Antimicrob Agents Chemother. 2012;56(7):4018–20.PubMedCentralPubMedGoogle Scholar
  40. 40.
    Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, et al. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr. 2004;37(5):1577–80.PubMedGoogle Scholar
  41. 41.
    Sustiva® [package insert]. Princeton: Bristol-Myers Squibb; 2008.Google Scholar
  42. 42.
    Intelence® [package insert]. Raritan: Tibotec Therapeutics; 2008.Google Scholar
  43. 43.
    Viramune® [package insert]. Ridgefield: Boehringer Ingelheim Pharmaceuticals, Inc.; 1996.Google Scholar
  44. 44.
    Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retrovir. 2010;26(11):1181–90.PubMedGoogle Scholar
  45. 45.
    Nuttall J, Hettema W, van Niekerk N, Nel A. Pharmacokinetics of monthly dapivirine vaginal microbicide rings (Ring-004) for HIV prevention [poster no. 44]. International Microbicides Conference; 15–18 Apr 2012; Sydney.Google Scholar
  46. 46.
    Chen BA, Panther L, Hoesley C, Hendrix C, van der Straten A, Husnik M, et al. Safety and pharmacokinetics/pharmacodynamics of dapivirine and maraviroc vaginal rings [abstract no. 41]. 21st Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2014; Boston.Google Scholar
  47. 47.
    Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49(11):4721–32.PubMedCentralPubMedGoogle Scholar
  48. 48.
    Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1–infected individuals. J Exp Med. 1997;185(4):621–8.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657–700.PubMedGoogle Scholar
  50. 50.
    Yeaman GR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, et al. Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology. 2004;113(4):524–33.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Klasse PJ, et al. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother. 2013;68(3):678–83.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother. 2012;56(5):2251–8.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Isentress® [package insert]. Whitehouse Station: Merck & Co., Inc.; 2007.Google Scholar
  54. 54.
    Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–54.PubMedGoogle Scholar
  55. 55.
    Tivicay® [package insert]. Research Triangle Park: GlaxoSmithKline; 2013.Google Scholar
  56. 56.
    Patterson KB, Prince HA, White N, et al. Pharmacokinetics of raltegravir in the blood plasma and genital tract of HIV-positive and HIV-negative women. 18th International AIDS Conference; 18–23 Jul 2010; Vienna.Google Scholar
  57. 57.
    Clavel C, Peytavin G, Tubiana R, Soulie C, Crenn-Hebert C, Heard I, et al. Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study). Antimicrob Agents Chemother. 2011;55(6):3018–21.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353–61.PubMedGoogle Scholar
  59. 59.
    Romano J, Kashuba A, Becker S, Cummins J, Turpin J, Veronese F. Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention. AIDS Res Hum Retrovir. 2013;29(11):1418–27.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Microbicide Trial Network (MTN). MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. 2011. http://www.mtnstopshiv.org/node/3909. Accessed 30 Dec 2013.
  61. 61.
    Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378(9787):279–81.PubMedCentralPubMedGoogle Scholar
  62. 62.
    Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010;464(7286):217–23.PubMedGoogle Scholar
  63. 63.
    Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito Taljaard M, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2013; Atlanta.Google Scholar
  64. 64.
    Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10(9):e1001511.PubMedCentralPubMedGoogle Scholar
  65. 65.
    Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PM, Nagaraja U, et al. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci USA. 2013;110(40):16145–50.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013;8(6):565–71.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Devlin B, Nuttall J, Wilder S, Woodsong C, Rosenberg Z. Development of dapivirine vaginal ring for HIV prevention. Antiviral Res. 2013;100(Suppl):S3–8.PubMedGoogle Scholar
  68. 68.
    Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010;39(4):1048–63.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog. 2010;6(5):e1000890.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet. 2013;382(9903):1515–24.PubMedGoogle Scholar
  71. 71.
    Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71(2):619–27.PubMedGoogle Scholar
  72. 72.
    Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50(10):3297–304.PubMedCentralPubMedGoogle Scholar
  73. 73.
    Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47(3):298–303.PubMedGoogle Scholar
  74. 74.
    Bleasby K, Hall LA, Perry JL, Mohrenweiser HW, Pritchard JB. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J Pharmacol Exp Ther. 2005;314(2):923–31.PubMedGoogle Scholar
  75. 75.
    Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, Augustijns P. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica. 2005;10–11(35):1055–66.Google Scholar
  76. 76.
    Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, et al. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retrovir. 2012;28(11):1412–21.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Brown KC, Patterson KB, Jennings SH, Malone SA, Shaheen NJ, Asherrince HM, et al. Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men. J Acquir Immune Defic Syndr. 2012;61(2):138–44.PubMedCentralPubMedGoogle Scholar
  78. 78.
    Khanvilkar K, Donovan MD, Flanagan DR. Drug transfer through mucus. Adv Drug Deliv Rev. 2001;48(2–3):173–93.PubMedGoogle Scholar
  79. 79.
    Patterson KB, Prince HA, Stevens T, Shaheen NJ, Dellon ES, Madanick RD, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS. 2013;27(9):1413–9.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Greener BN, Patterson KB, Prince HM, Sykes CS, Adams JL, Dumond JB, et al. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. J Acquir Immune Defic Syndr. 2013;64(1):39–44.PubMedGoogle Scholar
  81. 81.
    Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254–8.PubMedCentralPubMedGoogle Scholar
  82. 82.
    Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis. 2011;203(10):1484–90.PubMedCentralPubMedGoogle Scholar
  83. 83.
    Selzentry® [package insert]. Research Triangle Park: ViiV Healthcare; 2007.Google Scholar
  84. 84.
    Kelley CF, Haaland RE, Patel P, Evans-Strickfaden T, Farshy C, Hanson D, et al. HIV-1 RNA rectal shedding is reduced in men with low plasma HIV-1 RNA viral loads and is not enhanced by sexually transmitted bacterial infections of the rectum. J Infect Dis. 2011;204(5):761–7.PubMedCentralPubMedGoogle Scholar
  85. 85.
    Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedCentralPubMedGoogle Scholar
  86. 86.
    Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra25.Google Scholar
  87. 87.
    Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014;9(1):e83736.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Tindall B, Evans L, Cunningham P, McQueen P, Hurren L, Vasak E, et al. Identification of HIV-1 in semen following primary HIV-1 infection. AIDS. 1992;6(9):949–52.PubMedGoogle Scholar
  89. 89.
    Dyer JR, Gilliam BL, Eron JJ Jr, Cohen MS, Fiscus SA, Vernazza PL. Shedding of HIV-1 in semen during primary infection. AIDS. 1997;11(4):543–5.PubMedGoogle Scholar
  90. 90.
    Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol. 1996;70(5):3098–107.PubMedCentralPubMedGoogle Scholar
  91. 91.
    Byrn RA, Zhang D, Eyre R, McGowan K, Kiessling AA. HIV-1 in semen: an isolated virus reservoir. Lancet. 1997;350(9085):1141.PubMedGoogle Scholar
  92. 92.
    Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS. 1998;12(15):F181–9.PubMedGoogle Scholar
  93. 93.
    Vernazza PL, Eron JJ, Cohen MS, van der Horst CM, Troiani L, Fiscus SA. Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS. 1994;8(9):1325–9.PubMedGoogle Scholar
  94. 94.
    Diem K, Nickle DC, Motoshige A, Fox A, Ross S, Mullins JI, et al. Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV). AIDS Res Hum Retrovir. 2008;24(4):561–71.PubMedGoogle Scholar
  95. 95.
    Philpott S, Burger H, Tsoukas C, Foley B, Anastos K, Kitchen C, et al. Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J Virol. 2005;79(1):353–63.PubMedCentralPubMedGoogle Scholar
  96. 96.
    Ndovi TT, Parsons T, Choi L, Caffo B, Rohde C, Hendrix CW. A new method to estimate quantitatively seminal vesicle and prostate gland contributions to ejaculate. Br J Clin Pharmacol. 2007;63(4):404–20.PubMedCentralPubMedGoogle Scholar
  97. 97.
    van Praag RM, Repping S, de Vries JW, Lange JM, Hoetelmans RM, Prins JM. Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma. Antimicrob Agents Chemother. 2001;45(10):2902–7.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Cao YJ, Hendrix CW. Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment. Clin Pharmacol Ther. 2008;83(3):401–12.PubMedGoogle Scholar
  99. 99.
    Setchell BP. The functional significance of the blood-testis barrier. J Androl. 1980;1(1):3–10.Google Scholar
  100. 100.
    Mital P, Hinton BT, Dufour JM. The blood-testis and blood-epididymis barriers are more than just their tight junctions. Biol Reprod. 2011;84(5):851–8.PubMedGoogle Scholar
  101. 101.
    Holash JA, Harik SI, Perry G, Stewart PA. Barrier properties of testis microvessels. Proc Natl Acad Sci USA. 1993;90(23):11069–73.PubMedCentralPubMedGoogle Scholar
  102. 102.
    Bart J, Hollema H, Groen HJ, de Vries EG, Hendrikse NH, Sleijfer DT, et al. The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer. 2004;40(14):2064–70.PubMedGoogle Scholar
  103. 103.
    Pereira AS, Kashuba AD, Fiscus SA, Hall JE, Tidwell RR, Troiani L, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis. 1999;180(6):2039–43.PubMedGoogle Scholar
  104. 104.
    Anderson PL, Noormohamed SE, Henry K, Brundage RC, Balfour HH Jr, Fletcher CV. Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. Pharmacotherapy. 2000;20(8):917–22.PubMedGoogle Scholar
  105. 105.
    Taylor S, van Heeswijk RP, Hoetelmans RM, Workman J, Drake SM, White DJ, et al. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS. 2000;14(13):1979–84.PubMedGoogle Scholar
  106. 106.
    van Praag RM, van Heeswijk RP, Jurriaans S, Lange JM, Hoetelmans RM, Prins JM. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. Clin Infect Dis. 2001;33(8):e91–2.PubMedGoogle Scholar
  107. 107.
    Pereira AS, Smeaton LM, Gerber JG, Acosta EP, Snyder S, Fiscus SA, et al. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS Clinical Trials Group study 850). J Infect Dis. 2002;186(2):198–204.PubMedGoogle Scholar
  108. 108.
    Ghosn J, Chaix ML, Peytavin G, Rey E, Bresson JL, Goujard C, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS. 2004;18(14):1958–61.PubMedGoogle Scholar
  109. 109.
    Cruciani M, Liuzzi G, Chirianni A, Audagnotto S, Bonora S, Di Biagio A, et al. Penetration of didanosine in semen of HIV-1-infected men. J Antimicrob Chemother. 2006;57(6):1244–7.PubMedGoogle Scholar
  110. 110.
    Dumond JB, Reddy YS, Troiani L, Rodriguez JF, Bridges AS, Fiscus SA, et al. Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr. 2008;48(2):156–62.PubMedCentralPubMedGoogle Scholar
  111. 111.
    Vourvahis M, Tappouni HL, Patterson KB, Chen YC, Rezk NL, Fiscus SA, et al. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr. 2008;47(3):329–33.PubMedCentralPubMedGoogle Scholar
  112. 112.
    Antoniou T, Hasan S, Loutfy MR, Kovacs C, Brunetta J, Smith G, et al. Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men. J Acquir Immune Defic Syndr. 2013;62(2):e58–60.PubMedGoogle Scholar
  113. 113.
    Barau C, Delaugerre C, Braun J, de Castro N, Furlan V, Charreau I, et al. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. Antimicrob Agents Chemother. 2010;54(2):937–9.PubMedCentralPubMedGoogle Scholar
  114. 114.
    Calcagno A, Bonora S, D’Avolio A, Siccardi M, Simiele M, Chiesa M, et al. Raltegravir penetration in seminal plasma of healthy volunteers. Antimicrob Agents Chemother. 2010;54(6):2744–5.PubMedCentralPubMedGoogle Scholar
  115. 115.
    Antoniou T, Loutfy MR, Brunetta J, Smith G, Halpenny R, la Porte C. Pharmacokinetics of raltegravir in the semen of HIV-infected men. Antivir Ther. Epub 2014 Feb 12. doi:10.3851/IMP2750.
  116. 116.
    Tiraboschi JM, Niubo J, Curto J, Podzamczer D. Maraviroc concentrations in seminal plasma in HIV-infected patients. J Acquir Immune Defic Syndr. 2010;55(5):e35–6.PubMedGoogle Scholar
  117. 117.
    Lafeuillade A, Solas C, Chadapaud S, Hittinger G, Poggi C, Lacarelle B. HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen. J Acquir Immune Defic Syndr. 2003;32(4):462–4.PubMedGoogle Scholar
  118. 118.
    Sankatsing SU, Droste J, Burger D, Van Praag RM, Jurriaans S, Lange JM, et al. Limited penetration of lopinavir into seminal plasma of HIV-1-infected men. AIDS. 2002;16(12):1698–700.PubMedGoogle Scholar
  119. 119.
    Taylor S, Back DJ, Drake SM, Workman J, Reynolds H, Gibbons SE, et al. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother. 2001;48(3):351–4.PubMedGoogle Scholar
  120. 120.
    Taylor S, Back DJ, Workman J, Drake SM, White DJ, Choudhury B, et al. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS. 1999;13(7):859–60.PubMedGoogle Scholar
  121. 121.
    Taylor S, Jayasuriya AN, Berry A, Gilleran G, Dufty NE, Else L, et al. Darunavir concentrations exceed the protein-corrected EC(5)(0) for wild-type HIV in the semen of HIV-1-infected men. AIDS. 2010;24(16):2583–7.PubMedGoogle Scholar
  122. 122.
    van Leeuwen E, Ter Heine R, van der Veen F, Repping S, Beijnen JH, Prins JM. Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007;51(1):335–7.PubMedCentralPubMedGoogle Scholar
  123. 123.
    Vergara TR, Estrela RC, Suarez-Kurtz G, Schechter M, Cerbino-Neto J, Barroso PF. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil. Ther Drug Monit. 2006;28(2):175–9.PubMedGoogle Scholar
  124. 124.
    Chaudry NI, Eron JJ, Naderer OJ, Pereira AS, Wire MB, Fiscus SA, et al. Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. Clin Infect Dis. 2002;35(6):760–2.PubMedGoogle Scholar
  125. 125.
    Reddy YS, Gotzkowsky SK, Eron JJ, Kim JY, Fiske WD, Fiscus SA, et al. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J Infect Dis. 2002;186(9):1339–43.PubMedGoogle Scholar
  126. 126.
    Taylor S, Reynolds H, Sabin CA, Drake SM, White DJ, Back DJ, et al. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS. 2001;15(15):2051–3.PubMedGoogle Scholar
  127. 127.
    Avery LB, Bakshi RP, Cao YJ, Hendrix CW. The male genital tract is not a pharmacological sanctuary from efavirenz. Clin Pharmacol Ther. 2011;90(1):151–6.PubMedCentralPubMedGoogle Scholar
  128. 128.
    Vernazza PL, Gilliam BL, Flepp M, Dyer JR, Frank AC, Fiscus SA, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS. 1997;11(10):1249–54.PubMedGoogle Scholar
  129. 129.
    Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS. 2000;14(2):117–21.PubMedGoogle Scholar
  130. 130.
    Chakraborty H, Sen PK, Helms RW, Vernazza PL, Fiscus SA, Eron JJ, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS. 2001;15(5):621–7.PubMedGoogle Scholar
  131. 131.
    Thompson C, Sedykh A, Nicol M, Muratov E, Fourches D, Tropsha A, et al. Cheminformatics analysis to identify predictors of antiviral drug penetration into the female genital tract. AIDS Res Hum Retrovir. [Epub 2014 Feb 10].Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of PharmacyUniversity of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations